The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
暂无分享,去创建一个
V. Blanchette | C. Rothschild | C. Négrier | K. Pasi | J. Di Paola | A. Shapiro | T. Abshire | J. Lusher | M. Heisel | D. Roth | A. Cohen | W. Hoots
[1] L. Gooding. Children's. , 2005, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[2] K. Pasi,et al. Haemophilias A and B , 2003, The Lancet.
[3] G. Castaldo,et al. Haemophilia B: From Molecular Diagnosis to Gene Therapy , 2003, Clinical chemistry and laboratory medicine.
[4] M. Haase. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.
[5] M. Ragni,et al. Safety of the new generation recombinant factor concentrates , 2002, Expert opinion on drug safety.
[6] C. Kasper. Concentrate safety and efficacy , 2002, Haemophilia.
[7] B. Evatt,et al. Haemophilia 2002: emerging risks of treatment , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] K. Pasi,et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] J. Katz,et al. The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.
[10] C. Leissinger,et al. Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B , 2002, Transfusion.
[11] A. Shapiro,et al. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[12] J. Lusher. Inhibitor Antibodies to Factor VIII and Factor IX: Management , 2000, Seminars in thrombosis and hemostasis.
[13] C. Rothschild,et al. Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate , 1999, Thrombosis and Haemostasis.
[14] E. Thorland,et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] Gildea Jh. Human parvovirus B19--flushed in face though healthy (fifth disease and more). , 1998 .
[16] S. O'brien. Clinical challenges in chronic lymphocytic leukemia. , 1998, Seminars in hematology.
[17] J. Rouse,et al. Biochemical characterization of recombinant factor IX. , 1998, Seminars in hematology.
[18] K. Hanley,et al. The manufacturing process for recombinant factor IX. , 1998, Seminars in hematology.
[19] T. Charlebois,et al. Viral safety of recombinant factor IX. , 1998, Seminars in hematology.
[20] P. Garzone,et al. Clinical evaluation of recombinant factor IX. , 1998, Seminars in hematology.
[21] J. Gildea. Human parvovirus B19--flushed in face though healthy (fifth disease and more). , 1998, Pediatric nursing.
[22] M. Goossens,et al. Haemophilia B: database of point mutations and short additions and deletions--eighth edition , 1998, Nucleic Acids Res..
[23] J. Lusher,et al. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.
[24] M. Goossens,et al. Haemophilia B: database of point mutations and short additions and deletions, 7th edition , 1990, Nucleic Acids Res..
[25] J. Katz,et al. Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.
[26] N. Key,et al. Factor IX inhibitors and anaphylaxis in haemophilia B , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[27] B. Djulbegovic,et al. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B , 1996, American journal of hematology.
[28] M. Hannan,et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. , 1996, Thrombosis and Haemostasis.
[29] I. Warrier,et al. Safety of high doses of a monoclonal antibody‐purified factor IX concentrate , 1995, American journal of hematology.
[30] J. Montoro,et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting‐factor concentrates considered safe against human immunodeficiency and hepatitis C viruses , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.
[31] I. Scharrer. The need for highly purified products to treat hemophilia B. , 1995, Acta haematologica.
[32] H. Roberts,et al. Current management of hemophilia B. , 1993, Hematology/oncology clinics of North America.
[33] Y. Sultan. Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France , 1992, Thrombosis and Haemostasis.
[34] W. Kreuz,et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.
[35] C. M. Steel,et al. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy , 1992, British journal of haematology.
[36] S. Kajigaya,et al. First continuous propagation of B19 parvovirus in a cell line. , 1992, Blood.
[37] P. Saidi,et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. , 1992, Blood.
[38] M. Relling,et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. , 1991, Seminars in hematology.
[39] J. Lusher,et al. Thrombogenicity associated with factor IX complex concentrates. , 1991, Seminars in hematology.
[40] F. Church,et al. Antithrombin: structure and function. , 1991, Seminars in hematology.
[41] P. Saidi,et al. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate. , 1991, Seminars in hematology.
[42] P. Mannucci,et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. , 1990, Blood.
[43] M. Ragni,et al. Immune hemolysis by isohemagglutinins in factor IX concentrates , 1987, Transfusion.
[44] B. Furie,et al. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. , 1986, The Journal of biological chemistry.
[45] K. W. Backe,et al. [In the children's hospital]. , 1984, Krankenpflege Journal.
[46] D. Rees,et al. Molecular cloning of the gene for human anti-haemophilic factor IX , 1982, Nature.
[47] A. Imbriano. [Blood coagulation]. , 1955, La Semana medica.
[48] lhealtlhy youin-g,et al. Hospital for Sick Children , 1857, British medical journal.